Nektar Therapeutics
Income Statement
| Line Item | FY2010 | FY2009 |
|---|---|---|
| Revenue | $159.0M | $71.9M |
| Cost of Revenue | $25.7M | $30.9M |
| Gross Profit | $133.4M | $41.0M |
| Gross Margin | 83.9% | 57.0% |
| Operating Expenses | ||
| Research & Development | $108.1M | $95.1M |
| SG&A Expense | $41.0M | $41.0M |
| Operating Income | $-28.3M | $-95.1M |
| Operating Margin | -17.8% | -132.3% |
| Interest Expense | $11.2M | $12.2M |
| Pretax Income | $-37.1M | $-102.8M |
| Income Tax Expense | $881.0K | $-253.0K |
| Net Income | $-37.9M | $-102.5M |
| Net Margin | -23.9% | -142.5% |
| EPS (Basic) | $-0.40 | $-1.11 |
| EPS (Diluted) | $-0.40 | $-1.11 |
| Shares Outstanding (Basic) | 94.5M | — |
| Shares Outstanding (Diluted) | 94.5M | — |
| Dividends Per Share | — | — |